An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines.
about
Genetic variability among complete human respiratory syncytial virus subgroup A genomes: bridging molecular evolutionary dynamics and epidemiologyVaccines for the common coldHuman antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines.Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatmentRecombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzeesRecombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees.Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaRespiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant.Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.Active and passive immunisation against respiratory syncytial virus.Cytotoxic T-lymphocyte precursor frequencies in BALB/c mice after acute respiratory syncytial virus (RSV) infection or immunization with a formalin-inactivated RSV vaccineDifferential histopathology and chemokine gene expression in lung tissues following respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV- or BBG2Na-immunized mice.Respiratory syncytial virus vaccinesAnimal pneumoviruses: molecular genetics and pathogenesis.Gamma interferon-dependent protection of the mouse upper respiratory tract following parenteral immunization with a respiratory syncytial virus G protein fragmentAssembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins.Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus.The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein.Priming with live respiratory syncytial virus (RSV) prevents the enhanced pulmonary inflammatory response seen after RSV challenge in BALB/c mice immunized with formalin-inactivated RSV.Involvement of antibody, complement and cellular immunity in the pathogenesis of enhanced respiratory syncytial virus disease.Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and BSingle intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infectionStrain-specific reverse transcriptase PCR assay: means to distinguish candidate vaccine from wild-type strains of respiratory syncytial virusTwo distinct human parainfluenza virus type 1 genotypes detected during the 1991 Milwaukee epidemicSelection of cold-adapted mutants of human rotaviruses that exhibit various degrees of growth restriction in vitro.Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based human parainfluenza virus type 3 vaccines.Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease.Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.T cell source of type 1 cytokines determines illness patterns in respiratory syncytial virus-infected mice.The role of dendritic cells in innate and adaptive immunity to respiratory syncytial virus, and implications for vaccine development.Vaccines for the common cold.Novel recombinant DNA vaccine candidates for human respiratory syncytial virus: Preclinical evaluation of immunogenicity and protection efficiency.Biochemical characterizations of two temperature-sensitive and attenuated strains of respiratory syncytial virus subgroup B.Regulated but not constitutive human respiratory syncytial virus (HRSV) P protein phosphorylation is essential for oligomerization.Protection against respiratory syncytial virus infection by DNA immunization.Respiratory syncytial virus--how soon will we have a vaccine?Combining DNA and protein vaccines for early life immunization against respiratory syncytial virus in mice.Combination live respiratory virus vaccines.Development and validation of an enzyme linked immunosorbent assay for palivizumab serum determination.
P2860
Q21133803-FEE3B1B6-ED23-4B8B-ACD5-53C35F763369Q24201977-9D002E73-702E-421C-961C-B789B1EAC438Q33177627-00E07771-F4F5-4CD5-AE6F-256E718F6A70Q33558475-07A8F094-8F20-4761-BA56-07A513594D70Q33588916-EC26121B-D228-4D0D-8F58-A20106537C1FQ33605207-65CF138E-D0C6-4610-BD67-3009735A63F2Q33645414-D67337F3-212A-41C0-92C7-E1E418F8BAE7Q33707803-0112692F-DCD7-40E7-975E-D77B2856E9E3Q33738521-06568242-A7C5-4AC5-90C8-F154BC1E4287Q33776507-6EA50CB3-2354-4568-9C64-085CC86AA155Q33782438-59DDBB19-BC30-44CD-BF74-A5DA38427B9BQ33785332-04CA3C35-6856-41A9-911C-0315D5291C28Q33870528-F3563E59-9EBA-49BB-943F-DE3B4B417D77Q33975330-9E6F6E84-B08E-45C5-91EF-A365858B72BEQ34313560-BA34A9A6-704D-4FAD-90A8-4014D4611E8EQ34347904-40F7EA73-7C59-42F9-8F34-445BA1CB925EQ34457791-C3DBBB5E-456E-40E3-9DE0-BB22EB5D38E9Q35872191-75F6A34F-4B36-4F32-8634-28BD85BD16DDQ35889627-A7B849B2-2130-497E-994E-7D04263B554CQ35892441-E0F0567A-DEC6-46D9-A9CB-F13DD7DB98B0Q35987805-F7B95227-8D29-4BD1-92BD-E132FEFA9FF1Q36453608-788B09A9-C9CF-487C-8886-750E168A544FQ36483809-FD88A4FB-6F12-4B69-8BFC-6553187D75A8Q36527737-80AFDAB4-5E6D-410F-9A9C-C2DE824FCBB7Q36528756-CEA355C3-1464-4FEB-9E0D-21880346577BQ36637434-81CAF36F-F9B7-4D03-A503-958269CD8DA5Q36827280-D557DFB2-BE0E-44BC-A4D6-52E21CB969DDQ36922280-0CFD8B94-73A3-421E-A11B-B31193A20640Q37348134-11C94D6D-D5DF-4DBC-A389-891606BC11B5Q37366590-81C79C87-E558-454C-9CAD-540A38E703A5Q38068469-8D5CD986-E9D6-41CA-A484-A4D2C5C8A852Q38682527-9AEFF206-63E5-4288-B8F5-5B9BBF1F7062Q38921013-D85195E0-61AC-4FFE-B42E-92A9BF50EFB9Q39880109-434C9C43-85A7-4361-AB93-59239778C9ABQ40900083-53D426CF-ACAC-406F-848A-15CA04CE997CQ41907861-CC1DF5B8-A2A2-434F-B0D2-C9AC7FE6F73DQ42373593-63739C2D-8F35-4087-8F95-67C3DAC7A179Q45746586-49CC793B-E0F4-4030-9234-0446863BDDFDQ45787801-40E01C31-3154-44A6-9822-98FCF32781ABQ45806310-91BE3FF1-139D-4F32-9527-066A13D96BBF
P2860
An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
An update on approaches to the ...... virus type 3 (PIV3) vaccines.
@en
type
label
An update on approaches to the ...... virus type 3 (PIV3) vaccines.
@en
prefLabel
An update on approaches to the ...... virus type 3 (PIV3) vaccines.
@en
P2093
P1433
P1476
An update on approaches to the ...... virus type 3 (PIV3) vaccines.
@en
P2093
Chanock RM
Collins PL
Kulkarni AB
P356
10.1016/0168-1702(94)90059-0
P577
1994-04-01T00:00:00Z